Gelteq Limited · NASDAQ:GELS
Gelteq — Investor Presentation (December 2025)
21 slides from Gelteq's investor presentation, Dec 9, 2025
Slide 1: The Next Evolution in Oral Drug & Nutrient Delivery
The Ne xt E v ol ut ion in O r al D ru g & N utr ien t Deli v e ry © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. INVESTOR OVERVIEW DECEMBER 2025
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. Ce rt ain st a t emen ts in t hi s pr e s en t a t ion ma y con st i tut e “ fo rw a r d - looking st a t emen ts ” w i t hin t he meaning of t he P r i v a t e Sec ur i t ie s Li t iga t ion Refo r m
Slide 3: Gelteq (NASDAQ: GELS) Overview
A global clinical and s cience ba s ed com p an y t ha t ha s de v elo p ed a no v el d ru g deli v e ry p la t fo r m in an inge st ible gel fo r m Gel t e q sp eciali z e s in t he fo r m u la t ion , de v elo p men t and man u fac tur ing of gel pr od u c ts fo r licen s ed p a rt ne rs Fo u nded
Slide 4: Gelteq - Company Highlights
GELTEQ - COMPANY HIGHLIGHTS Inno v a t i v e d ru g and n utr ien t deli v e ry p la t fo r m t ha t i s ma r ke t r ead y Po rt folio of n utr ace ut ical pr od u c ts al r ead y de v elo p ed and s ale s r ead y Gel t e q hold s m u l t i p le p a t en t familie s t ha t co v e r a r ange of a pp
Slide 5: Research and Validation Partner
RESEARCH AND VALIDATION PARTNER Engaged Mona s h Uni v e rs i ty ’ s Medicine s Man u fac tur ing Inno v a t ion Cen tr e ( MMIC ) t o bo t h v e r if y and t e st o ur s cien t ifc me t hodologie s. Mona s h Uni v e rs i ty i s a global leade r in Pha r mace ut ical Science # 4 Pha r mac y and Pha
Slide 6: Mission Statement
To im pr o v e t he li v e s of h u man s and animal s b y making d ru g and n utr ace ut ical pr od u c ts mo r e acce ss ible and ea s ie r t o con su me © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. MISSION STATEMENT
Slide 7: Medication Compliance Is a Universal Problem
MEDICATION COMPLIANCE IS A UNIVERSAL PROBLEM © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential.
Slide 8: Industry Challenges
INDUSTRY CHALLENGES Pa t en t lifec y cle pr e ssur e s a s d ru g p a t en ts e xp i r e B r inging a 90% r e v en u e d r o p w hen gene r ic s a rr i v e ** Pill A v e rs ion and S w allo w ing i ssu e s ~40% of con su me rs stru ggle w i t h sw allo w ing supp lemen ts* Con v enience Con su me r
Slide 9: Industry Challenges: Poorly Soluble Drugs
The o r al deli v e ry of oil - s ol u ble ( li p o p hilic ) o r in s ol u ble com p o u nd s a r e a majo r challenge fo r p ha r mace ut ical com p anie s. 40 – 60 % of ma r ke t ed d ru g s and up t o 90 % of di s co v e ry candida t e s a r e p oo r l y s ol u ble * Pha r mace ut ical com p ani
Slide 10: Imagine
Imagine if t he r e w a s an inno v a t i v e deli v e ry p la t fo r m t ha t co u ld add r e ss t he challenge s t ha t p ha r mace ut ical and n utr ace ut ical com p anie s a r e e xp e r iencing © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. IMAGINE
Slide 11: The Gelteq Solution
THE GELTEQ SOLUTION © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. Gel t e q ’ s p a t en t ed gel deli v e ry can p o t en t iall y syst em s ol v e man y of t he p ha r mace ut ical and supp lemen t ind ustry ’ s challenge s - f r om p oo r adhe r ence and p ill fa t ig u
Slide 12: Gelteq Advantages - Water Soluble Compounds
T r ial r e su l ts s ho w ed Gel t e q ’ s inno v a t i v e t echnolog y fo r w a t e r s ol u ble com p o u nd s w a s able t o : Im pr o v e bioa v ailabili ty ( o v e r all ab s o rpt ion ) b y o v e r 40 % . P r o v ide fa st e r ab s o rpt ion fo r an API Enhance ing r edien t ab s o rpt ion w
Slide 13: Gelteq Advantages - Oil Soluble Compounds
GELTEQ ADVANTAGES - OIL SOLUBLE COMPOUNDS time post - administration (hours) Graph = Gelteq trial results with an oil soluble drug and FDA approved product T r ial r e su l ts s ho w ed Gel t e q ’ s inno v a t i v e t echnolog y fo r oil s ol u ble com p o u nd s w a s able t o : Ha v e 300 % fa st
Slide 14: Gelteq Is Reimagining the Administered Dose
GELTEQ IS REIMAGINING THE ADMINISTERED DOSE © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. Gel t e q pr od u c ts can be deli v e r ed in a w ell e st abli s hed p ackaging fo r ma t t ha t i s w ell ado pt ed in t he ma r ke t... d r i v en b y con v enience VS
Slide 15: Gelteq Can Solve Industry Challenges
GELTEQ CAN SOLVE INDUSTRY CHALLENGES © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. Pa t en t lifec y cle pr e ssur e s a s d ru g p a t en ts e xp i r e Pill A v e rs ion and S w allo w ing i ssu e s Con v enience Poo r adhe r ence C r o w ded ma r ke ts Inabili ty t o hold
Slide 16: Gelteq Markets
GELTEQ MARKETS © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. Gel t e q ’ s p la t fo r m i s able t o w o r k ac r o ss t he belo w v e rt ical s. We offe r a com p le t e end - t o - end s e rv ice fo r o ur licen s ed p a rt ne rs. HUMAN HEALTH H u man Pha r mace ut ical
Slide 17: Market Opportunity (Human Health)
2024 2030 0 500 1000 1500 2000 2024 2034 0 500 1000 1500 2000 MARKET OPPORTUNITY ( HUMAN HEALTH ) The global p ha r mace ut ical ma r ke t Global n utr ace ut ical / supp lemen t ma r ke t $ 1 , 645.7 B $ 591.1 B 6.12 % CAGR 7.6 % CAGR $ 2 , 350.4 B $ 919.1 B So ur ce: G r and Vie w Re s ea r ch . (
Slide 18: Market Opportunity (Animal Health)
2024 2035 35 30 25 20 15 10 5 0 MARKET OPPORTUNITY ( ANIMAL HEALTH ) Global p e t p ha r mace ut ical ma r ke t $ 13.2B 7.85% CAGR $ 30.3B Gelteq makes supplement and medication delivery simple and stress - free for pets , pet owners , and veterinarians alike. 2023 2030 © Gelteq Limited 2025. All Ri
Slide 19: Gelteq B2B Strategy
O ur str a t eg y i s t o p a rt ne r w i t h p ha r mace ut ical and supp lemen t com p anie s t o de v elo p ʁ man u fac tur e ʁ and licen s e gel ʉ ba s ed pr od u c ts. © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. GELTEQ B 2 B STRATEGY We a r e c urr en t l y foc us
Slide 20: Research & Development Pipeline Snapshot
RESEARCH & DEVELOPMENT PIPELINE SNAPSHOT © Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential. Pain Managemen t Alle r g y Diabe t e s Weigh t Managemen t Medicinal Cannabi s Men t al Heal t h Refl ux ( GERD ) An t i p a r a s i t ic Ve t e r ina r ian Oncolog y GeRX - 761 GeRX - 5
Slide 21: Investor Relations Contacts
Da rr o w A ss ocia t e s Ma tt K r e ps Managing Di r ec t o r A ust in, Te x a s Uni t ed S t a t e s T: 214 - 597 - 8200 mk r e ps @ da rr o w i r. com In v e st o r Rela t ion s Gel t e q Na t han Gi v oni, CEO Mona s h Inno v a t ion Lab s G .60 , 22 Alliance Lane Cla yt on 3800 Vic t o r ia A